Treace Medical Concepts - TMCI Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year target prices for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $27.00 to $29.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.

Treace Medical Concepts' stock was trading at $22.99 at the start of the year. Since then, TMCI stock has increased by 3.5% and is now trading at $23.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our TMCI earnings forecast.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of $21.62 million for the quarter, compared to the consensus estimate of $21.06 million. Treace Medical Concepts had a negative net margin of 35.87% and a negative trailing twelve-month return on equity of 51.67%.

Treace Medical Concepts updated its FY 2022 earnings guidance on Friday, January, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $141.20 million-$141.70 million, compared to the consensus revenue estimate of $137.01 million.

(TMCI) raised $150 million in an initial public offering on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.14%), Emerald Mutual Fund Advisers Trust (1.70%), Allspring Global Investments Holdings LLC (0.86%), Calamos Advisors LLC (0.29%), Essex Investment Management Co. LLC (0.25%) and Lisanti Capital Growth LLC (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends.

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMCI stock can currently be purchased for approximately $23.79.

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $1.32 billion and generates $94.42 million in revenue each year. The company earns $-20,550,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

The company employs 248 workers across the globe.

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.